AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31986446 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a medicine take-back program
Number of subjects: 0
Study 31986446 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay for a medicine disposal program
Number of subjects: 0
Study 31986446 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing willingness to participate
Number of subjects: 0
Study 31986446 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing willingness to pay
Number of subjects: 0
Study 31986446 — intervention group
Group type: EXPERIMENTAL
Intervention: Current disposal practices
Number of subjects: 0
Study 31490546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 884
Study 31490546 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 884
Study 28916992 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 (400 IU)
Number of subjects: 159
Study 28916992 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 (1000 IU)
Number of subjects: 159
Study 28916992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 25982649 — intervention group
Group type: EXPERIMENTAL
Intervention: XPF 0.3 mm caps
Number of subjects: 197
Study 25982649 — intervention group
Group type: EXPERIMENTAL
Intervention: XPF 0.5 mm caps
Number of subjects: 197
Study 25982649 — intervention group
Group type: COMPARATOR
Intervention: Standard fabric caps
Number of subjects: 197
Study 23664161 — intervention group
Group type: EXPERIMENTAL
Intervention: MiroCam (MC)
Number of subjects: 105
Study 23664161 — intervention group
Group type: COMPARATOR
Intervention: PillCam (PC)
Number of subjects: 105
Study 21935794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia group (laparotomy and tying of the superior mesenteric artery)
Number of subjects: 21
Study 21935794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 21935794 — intervention group
Group type: COMPARATOR
Intervention: Sham group (laparotomy without ischemia)
Number of subjects: 21
Study 19646048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally enhanced beans (NEB)
Number of subjects: 0
Study 19646048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally enhanced maize (NEM)
Number of subjects: 0
Study 19646048 — intervention group
Group type: COMPARATOR
Intervention: Conventional beans (CB)
Number of subjects: 0
Study 19646048 — intervention group
Group type: COMPARATOR
Intervention: Conventional maize (CM)
Number of subjects: 0
Study 17493496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of epinephrine
Number of subjects: 0
Study 17493496 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation
Number of subjects: 0
Study 17493496 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vasoconstrictors
Number of subjects: 0
Study 15505276 — intervention group
Group type: COMPARATOR
Intervention: TAM 30 mg/d for 3 years
Number of subjects: 338
Study 15505276 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI 30 mg on days 1, 8, and 15 every 28 days for six cycles plus TAM 30 mg/d for 3 years
Number of subjects: 338
Study 11737422 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy for 6 months
Number of subjects: 32
Study 11737422 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study 9559107 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure (mean concentration of 2.37 ppm)
Number of subjects: 13
Study 9559107 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 students without FA exposure)
Number of subjects: 13
Study 8145901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physical rehabilitation program for 4 weeks
Number of subjects: 0
Study 8145901 — intervention group
Group type: COMPARATOR
Intervention: Normal physical activity for 4 weeks
Number of subjects: 0
Study 3481276 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective supporting appliance during intubation
Number of subjects: 30
Study 3481276 — intervention group
Group type: COMPARATOR
Intervention: Prolonged orotracheal intubation without protective appliance
Number of subjects: 30
Study 29792232 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-guided goal-directed hemodynamic therapy (GDHT)
Number of subjects: 128
Study 29792232 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 27271724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical debridement, bone graft, and instrumentation (Group A)
Number of subjects: 74
Study 27271724 — intervention group
Group type: COMPARATOR
Intervention: Isolated posterior instrumentation without debridement (Group B)
Number of subjects: 74
Study 27271724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 74
Study 27271724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical debridement (Group A)
Number of subjects: 74
Study 25285430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedonic story
Number of subjects: 0
Study 25285430 — intervention group
Group type: COMPARATOR
Intervention: Eudaimonic story
Number of subjects: 0
Study 21938436 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep
Number of subjects: 23
Study 21938436 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep in mild OSA patients
Number of subjects: 23
Study 21938436 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep in moderate to severe OSA patients
Number of subjects: 23
Study 21938436 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep in mild OSA patients (supine position)
Number of subjects: 23
Study 21938436 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for sleeping with upper and lower dentures
Number of subjects: 23
Study 15735202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment for 10 days (T(2)D+); plasma glucose 5.5 ± 0.2 mmol/l
Number of subjects: 8
Study 15735202 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of all antidiabetic medications for 2 weeks (T(2)D-); plasma glucose 12.6 ± 1.0 mmol/l
Number of subjects: 8
Study 15735202 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight-matched and lean nondiabetic subjects)
Number of subjects: 8
Study 11895895 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL-2 antisense oligonucleotide (G3139) at 6.9 mg/kg/day
Number of subjects: 35
Study 11895895 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL-2 antisense oligonucleotide (G3139)
Number of subjects: 35
Study 10332543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salmon calcitonin 200 IU
Number of subjects: 0
Study 10332543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin
Number of subjects: 0
Study 10332543 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term studies using intranasal calcitonin
Number of subjects: 0
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV infection
Number of subjects: 224
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV infection
Number of subjects: 224
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV infection
Number of subjects: 224
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 224
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV infection
Number of subjects: 224
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV infection (attributed cases)
Number of subjects: 224
Study 7676060 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral spread of infections agents
Number of subjects: 224
Study 2202902 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (50 to 100 mg per square meter of body-surface area per day)
Number of subjects: 103
Study 2202902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 6117260 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin administered 12 hours before operation
Number of subjects: 22
Study 6117260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31736382 — intervention group
Group type: EXPERIMENTAL
Intervention: Chefs in Action program (3 cooking workshops)
Number of subjects: 25
Study 31736382 — intervention group
Group type: COMPARATOR
Intervention: Single cooking workshop (comparison group 1, n=16)
Number of subjects: 25
Study 31736382 — intervention group
Group type: COMPARATOR
Intervention: Single cooking workshop (comparison group 3, n=24)
Number of subjects: 25
Study 31736382 — intervention group
Group type: COMPARATOR
Intervention: Single cooking workshop (comparison group 2, n=36)
Number of subjects: 25
Study 30959146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted medication protocol
Number of subjects: 42
Study 30959146 — intervention group
Group type: COMPARATOR
Intervention: Fixed medication protocol
Number of subjects: 42
Study 28381416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/day for 21 days of a 28-day cycle)
Number of subjects: 102
Study 28381416 — intervention group
Group type: COMPARATOR
Intervention: Investigator's Choice (IC) including gemcitabine, rituximab, etoposide, or oxaliplatin
Number of subjects: 102
Study 28381416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 102
Study 28381416 — intervention group
Group type: COMPARATOR
Intervention: Investigator's Choice (IC)
Number of subjects: 102
Study 28381416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (non-GCB subtype)
Number of subjects: 102
Study 28381416 — intervention group
Group type: COMPARATOR
Intervention: Investigator's Choice (IC) (non-GCB subtype)
Number of subjects: 102
Study 28381416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (GCB subtype)
Number of subjects: 102
Study 28381416 — intervention group
Group type: COMPARATOR
Intervention: Investigator's Choice (IC) (GCB subtype)
Number of subjects: 102
Study 25151065 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 223
Study 25151065 — intervention group
Group type: COMPARATOR
Intervention: Group therapy
Number of subjects: 223
Study 23842846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer
Number of subjects: 660
Study 23842846 — intervention group
Group type: COMPARATOR
Intervention: CardioSEAL-STARflex
Number of subjects: 660
Study 23842846 — intervention group
Group type: COMPARATOR
Intervention: Helex
Number of subjects: 660
Study 21459902 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 0
Study 21459902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18652322 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation therapy
Number of subjects: 120
Study 18652322 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 120
Study 18652322 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 120
Study 16875928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (low dosage)
Number of subjects: 253
Study 16875928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (high dosage)
Number of subjects: 253
Study 16875928 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (low, medium, high dosages)
Number of subjects: 253
Study 16875928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 12629054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (Fluzole 100 mg/day) starting from the sixth irradiation session throughout the treatment
Number of subjects: 80
Study 12629054 — intervention group
Group type: COMPARATOR
Intervention: Control group without specific prophylaxis (fluconazole only when mycotic infections appeared)
Number of subjects: 80
Study 12629054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole group
Number of subjects: 80
Study 12629054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 12629054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (Fluzole 100 mg/day)
Number of subjects: 80
Study 11111968 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of cyclosporine and replacement with anti-thymocyte globulin (ATG)
Number of subjects: 0
Study 9311220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (2 ml, 1 mg)
Number of subjects: 75
Study 9311220 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml of 0.9% saline)
Number of subjects: 75
Study 9311220 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1 ml, 0.5 mg) and neostigmine (2 ml, 1 mg)
Number of subjects: 75
Study 8225701 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaprose
Number of subjects: 20
Study 8225701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3760520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy and appendectomy
Number of subjects: 120
Study 3760520 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy alone
Number of subjects: 120
Study 29482648 — intervention group
Group type: EXPERIMENTAL
Intervention: high support career guidance intervention
Number of subjects: 140
Study 29482648 — intervention group
Group type: COMPARATOR
Intervention: service as usual
Number of subjects: 140
Study 27077358 — intervention group
Group type: EXPERIMENTAL
Intervention: App variants with active contagion strategies and increased duration of use
Number of subjects: 9042
Study 27077358 — intervention group
Group type: COMPARATOR
Intervention: App variants without active contagion strategies
Number of subjects: 9042
Study 24211309 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 707
Study 24211309 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 707
Study 23011423 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent reflexology sessions and cortexin treatment (10 mg, 10 injections)
Number of subjects: 60
Study 23011423 — intervention group
Group type: COMPARATOR
Intervention: Reflexology treatments only
Number of subjects: 60
Study 23011423 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent reflexology with cortexin
Number of subjects: 60
Study 19897055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 19897055 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 18632186 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 625
Study 15737667 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free mixture (31.2 g of amino acids)
Number of subjects: 48
Study 15737667 — intervention group
Group type: COMPARATOR
Intervention: Control mixture (33.2 g of amino acids)
Number of subjects: 48
Study 14523211 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic sugar powder
Number of subjects: 244
Study 14523211 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (4% detergent water solution)
Number of subjects: 244
Study 10880033 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intervention group
Number of subjects: 144
Study 10880033 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group
Number of subjects: 144
Study 10880033 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 144
Study 8895639 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 262
Study 8895639 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 262
Study 2071262 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg theophylline
Number of subjects: 12
Study 2071262 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12
Study 2071262 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg theophylline followed by 400 mg rufloxacin after 30 min
Number of subjects: 12
Study 2071262 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine followed by 400 mg rufloxacin after 30 min
Number of subjects: 12
Study 6357692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Bay K 9320) 20 mg, three times daily for three weeks
Number of subjects: 24
Study 6357692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6357692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Bay K 9320)
Number of subjects: 24
Study 31995024 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg for three months
Number of subjects: 32
Study 31995024 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy subgroup with Esomeprazole
Number of subjects: 32
Study 31995024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no esomeprazole)
Number of subjects: 32
Study 30744298 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based diabetes self-management intervention for 3 months
Number of subjects: 500
Study 28577505 — intervention group
Group type: EXPERIMENTAL
Intervention: UP+TAU
Number of subjects: 29
Study 28577505 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 29
Study 25725426 — intervention group
Group type: EXPERIMENTAL
Intervention: High saturated fat meal
Number of subjects: 42
Study 25725426 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil meal
Number of subjects: 42
Study 25725426 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness assessment
Number of subjects: 42
Study 24429918 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive therapeutic exercise
Number of subjects: 48
Study 24429918 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapeutic exercise
Number of subjects: 48
Study 22230918 — intervention group
Group type: EXPERIMENTAL
Intervention: 29-h total sleep deprivation (TSD)
Number of subjects: 10
Study 22230918 — intervention group
Group type: COMPARATOR
Intervention: Control (normal night)
Number of subjects: 10
Study 19669019 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal inspired fraction of oxygen
Number of subjects: 20
Study 19669019 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary oxygen administration
Number of subjects: 20
Study 19669019 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hyperoxia
Number of subjects: 20
Study 17438407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate hydrochloride 100 mg 3 times per day orally for 12 weeks
Number of subjects: 21
Study 17438407 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 21
Study 15455745 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 45
Study 15455745 — intervention group
Group type: COMPARATOR
Intervention: Barrier membranes (control)
Number of subjects: 45
Study 11181869 — intervention group
Group type: EXPERIMENTAL
Intervention: GKI infusion (500 ml 10% glucose, 20 mmol potassium chloride, 16 units of insulin)
Number of subjects: 145
Study 11181869 — intervention group
Group type: COMPARATOR
Intervention: Control therapy with 154 mmol/l (0.9%) saline at 100 ml/h for 24 hours
Number of subjects: 145
Study 10211539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg daily for 9 days
Number of subjects: 24
Study 10211539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10211539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 24
Study 7752669 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0
Study 7752669 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term physical exercise at a sufficiently intense level
Number of subjects: 0
Study 7752669 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0
Study 2620532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervagem (1 mg vaginal suppository for 4 hours)
Number of subjects: 40
Study 2620532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan (osmotic dilator intracervically for 4 hours)
Number of subjects: 40
Study 1247222 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (41.0 +/- 5.4 Hz; 2 mm amplitude) applied to the back for one hour
Number of subjects: 10
Study 1247222 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 10
Study 31764462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 10
Study 31764462 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation
Number of subjects: 10
Study 31764462 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep
Number of subjects: 10
Study 29605624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium-olodaterol 5 μg-5 μg once daily
Number of subjects: 7880
Study 29605624 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 5 μg once daily
Number of subjects: 7880
Study 29605624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 7880
Study 26537308 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex, 20 sessions
Number of subjects: 5
Study 24730708 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study 24730708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22610452 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline, nebulized twice daily for 48 weeks
Number of subjects: 321
Study 22610452 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline, nebulized twice daily for 48 weeks
Number of subjects: 321
Study 22610452 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline
Number of subjects: 321
Study 22610452 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline
Number of subjects: 321
Study 20415801 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol rinse (20 mL of an aqueous solution of xylitol twice daily for 60 seconds, dose: 4.4 g/day)
Number of subjects: 105